General DNA synthesis and mitosis inhibition

The term "General DNA synthesis and mitosis inhibition" refers to a broad category of cellular and pharmacological interventions that disrupt both the replication of DNA (S-phase) and the subsequent process of mitosis. This effect can result from various molecular mechanisms, including inhibition of DNA polymerases, depletion of nucleotide pools, disruption of DNA replication licensing or firing (via CDC6, CDC7, etc.), or targeting mitotic kinases (such as CDK1 or PLK1). These interventions are commonly utilized in cancer chemotherapy, as rapidly dividing tumor cells are more susceptible to cell cycle disruption. However, since the processes of DNA replication and mitosis are critical to all dividing cells, non-specific inhibition has pronounced effects on normal tissues with high proliferative rates, leading to notable side effects. This entry should not be mapped to a single molecular target; instead, it is a functional annotation involving multiple molecular entities and pathways central to the cell division cycle.

Inhibitors of DNA synthesis act mainly by blocking DNA polymerases, nucleotide supply, or by damaging DNA, resulting in S-phase arrest. Mitosis inhibitors block progression at mitosis, commonly by interfering with spindle formation or inactivating mitotic kinases.